A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors
Clinical trial NCT04431726 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04431726
- Sponsor
- Hoffmann-La Roche
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-02-04
- Primary completion
- 2023-05-22
- Enrollment
- 55
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.